In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis. We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis. To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G 1 phase of the cell cycle (up to 80%) and activation of apoptosis (50%). These data are associated with an increase of p27 kip1 levels and a signi®cant reduction of the cdk2-associated kinase activity. In addition, we show that an ectopic overexpression of p27 kip1 in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G 1 arrest and activates apoptosis by increasing p27 kip1 content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G 1 checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells. Oncogene (2001) 20, 2814 ± 2825.
In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis. We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis. To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G 1 phase of the cell cycle (up to 80%) and activation of apoptosis (50%). These data are associated with an increase of p27 kip1 levels and a signi®cant reduction of the cdk2-associated kinase activity. In addition, we show that an ectopic overexpression of p27 kip1 in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G 1 arrest and activates apoptosis by increasing p27 kip1
Introduction
The c-myc gene encodes a nuclear phosphoprotein with extremely short half-life, which has been widely demonstrated to play a central role in the proliferation and dierentiation processes of normal cells. Following mitogenic stimulation, Myc is rapidly induced in quiescent cells thus participating in the cascade of events that result in mitogenesis (Ryan and Birnie, 1996; Dang, 1999; Schmidt, 1999) . Myc protein expression remains elevated in proliferating cells and c-myc mRNA levels are stable throughout the phases of the cell cycle, suggesting that c-myc is required for continuous cell proliferation. The deregulation of the c-myc gene has been shown to be involved in the establishment of many types of human malignancy (Dang, 1999) , however, c-myc deregulation is insucient to cause neoplasm by itself. The oncogenic potential of c-myc could simply be ascribed to its implication as a direct regulator of the cell cycle machinery, c-myc being poised at the intersection between cell growth and the cell cycle control. Consistent with the hypothesis that the loss of coordination between cell growth and DNA synthesis destabilizes cell proliferation, alterations in cell growth control can cause apoptosis in Myc-overexpressing cells. Indeed, Evan et al. (1992) demonstrated that removal of serum from growth media of Myc-overexpressing Rat1 ®broblasts induces dramatic apoptosis. Similarly, activation-induced apoptosis through the CD3-T cell receptor in T-cell hybridomas was blocked by antisense oligodeoxynucleotides targeting c-myc mRNA (Shi et al., 1992) . This could simply re¯ect the loss of coordination of growth processes in a cell that cannot limit its DNA synthesis. On the other hand, data are reported in literature which demonstrate that a down-regulation of the Myc protein by using c-myc antisense oligodeoxynucleotides induces apoptosis in BV173 leukemia cells (Skorski et al., 1995) as well as in HL60 cells (Kimura et al., 1995) . In addition engagement of the B-cell receptor of WEHI 231 immature lymphoma cells led to a drop in Myc protein levels which resulted in the induction of apoptosis (Ezhevsky et al., 1996; Wu et al., 1999; Fischer et al., 1994) . Furthermore, we have previously demonstrated that Myc down-regulation caused a signi®cant inhibition of cell proliferation and induced apoptosis in human melanoma experimental models (Leonetti et al., 1996; Citro et al., 1998) . Although deregulation of melanoma cell growth has been widely associated with mutations in the p16-cyclin D/cdk4-pRb pathway (Bartkova et al., 1996; Maelandsmo et al., 1996) , an increasing number of recent reports showed that the c-myc gene also plays a role in the melanoma pathogenesis (Castellano and Parmiani, 1999; Schraml et al., 1999; Schlagbauer-Wadl et al., 1999; Ross and Wilson, 1998) .
To gain insight into the molecular events regulated by c-myc in human melanoma cells, we developed a suitable experimental model that allows modulation of Myc protein synthesis; this was achieved by originating stable cell clones expressing inducible c-myc antisense mRNA. This avoided using modi®ed oligodeoxynucleotides to inhibit gene expression. In fact, it is well known that modi®ed oligomers, besides sequencespeci®c eects, could also have non-antisense activity which could make the understanding of the underlying genetic mechanism dicult (Stein, 1996 (Stein, , 1998 Crooke, 1996; Krieg and Stein, 1995) .
Furthermore, since it has been reported in the literature that over-expression of the cyclin-dependent kinase inhibitor p27 kip1 is able to promote apoptosis in several mammalian tumor cell lines, including breast, lung, colon, cervical carcinoma and melanoma (Katayose et al., 1997; Wang et al., 1997) , as well as in a line of B-cell lymphoma after treatment with anti-IgM (Ezhevsky et al., 1996; Wu et al., 1999; Fischer et al., 1994) , the eects of c-myc inhibition on p27 kip1 protein expression have also been investigated. Data herein reported demonstrate, for the ®rst time in melanoma cells, that the inhibitory eect on M14 melanoma cell proliferation caused by Myc protein down-regulation can activate apoptosis by increasing the levels of p27 kip1 .
Results
Expression of the p16, cyclin D1 and cdk4 in M14 melanoma cells
Since deregulation of melanoma cell growth has been mainly associated with alterations in the p16-cyclin D1/ cdk4-pRb pathway, we have ®rst characterized the M14 melanoma cell line for the expression of cyclin D1, cdk4 and p16 (Figure 1 ). Western blot analysis revealed that p16 is down-regulated in M14 cells as compared with normal peripheral lymphocytes, used as control cells. Indeed, to visualize detectable levels of p16 in M14 cells, fourfold more protein amount, with respect to the normal lymphocytes, had to be loaded on the acrylamide gel. Cyclin D1 as well as cdk4 were found overexpressed in M14 cells as compared to the normal cells, the increase of cyclin D1 and cdk4 levels being 2.4-fold and sixfold, respectively.
Inducible expression of c-myc antisense RNA inhibits cell proliferation in M14 cells
In order to investigate the molecular pathways regulated by c-myc involved in the activation of apoptosis in M14 melanoma cells, we developed a suitable tumor experimental model in which the expression of the Myc protein can be modulated. To reduce the levels of Myc protein expression we established a M14 cell line stably expressing a hormone-inducible c-myc antisense (AS) RNA. M14 cells were co-transfected with either the pINDc-myc AS constructs or the pINDneo empty vector, together with the pVgRXR plasmid, encoding for the ecdysone receptor and carrying the zeocyn resistance. G418/ zeocyn-resistant clones were isolated, under hormonefree conditions, after a selection period of 3 weeks. These clones were treated with 20 mM of hormone (ponasterone A) and scored for hormone inducible inhibition of cell proliferation. Ten dierent pINDcmyc AS clones displayed inhibition of cell proliferation, already evident after 24 h of induction with the hormone, ranging from 30 ± 60% (data not shown). The control clones exposed to the same ponasterone concentration did not show any signi®cant inhibition of the proliferation rate. Therefore, for further experiments the pINDc-myc AS clone showing the highest inhibition of cell proliferation upon hormoneexposure, was chosen. As control we used one of the pINDneo clones. To determine the optimal schedule of hormone treatment pINDc-myc AS cells were exposed to dierent concentrations of ponasterone A (5, 10 and 20 mM). After addition of 20 mM ponasterone an inhibition of cell proliferation of 38, 42 and 40% was observed in pINDc-myc AS cells at 24, 48 and 72 h, respectively, as compared with the control cells transfected with the empty vector (pINDneo; Figure 2a ). The pINDc-myc AS clone continuously exposed to 5 or 10 mM ponasterone did not elicit signi®cant inhibition of cell growth up to 72 h after induction. The cell proliferation rate of control cells The inhibition of cell proliferation observed after treatment of the pINDc-myc AS cell clone with a bolus of 20 mM ponasterone is consistent with the reduction of Myc protein expression, as detected by Western blot analysis performed at 24 h after induction (Figure 2b ). Relative densitometric analysis of the blots, normalized versus HSP 72/73 levels, showed that this treatment was able to reduce by about twofold the Myc protein content as compared to that of control cells. On the contrary, no signi®cant reduction in the level of Myc protein after exposure of pINDc-myc AS cells to 5 or 10 mM ponasterone was observed. Based on these results, all subsequent experiments were conducted using 20 mM ponasterone, to eciently down-regulate Myc protein in pINDc-myc AS M14 clone.
The cell growth inhibitory eect of a single dose 20 mM ponasterone was partially lost after 72 h. Thus, in order to better evidence the eects produced by maintaining a long-lasting low level of Myc protein into exponentially proliferating M14 cells, we determined the optimal schedule of hormone administration able to maintain Myc expression at a level critical for cell proliferation in pINDc-myc AS cell clone. To this end we measured the eect of repeated doses of ponasterone A. Figure 3a shows that a dose of 20 mM ponasterone repeated every 24 h, resulted in a signi®cant reduction of cell growth. After 24 h of hormone exposure we observed a cell growth inhibition of about 30%, a value similar to that obtained after 24 h with the previous regimen of hormone treatment. The reduction of cell proliferation became more signi®cant at 48 h from the start of hormone treatment (two doses of ponasterone), reaching values of 70% of growth inhibition (versus the 42% obtained with the single-dose regimen). After 72 h of hormone treatment, when the cells received a triple dose of ponasterone, the growth inhibition remained at a value of 78%. Even if exposed to a triple dose of ponasterone, empty vector transfected cells did not show signi®cant cell growth inhibition as compared to the parental cell line proliferation.
The levels of transcripts of both ectopic c-myc AS and endogenous c-myc were determined by semiquantitative RT ± PCR analysis, using suitable pairs of primers as indicated in Figure 3b (bottom). Figure  3b (top) shows the RT ± PCR analysis of total RNA extracted from the control clone (pINDneo) and the pINDc-myc AS clone exposed for 24 h to 20 mM of ponasterone. The PCR ampli®cation was performed at various numbers of cycles, as indicated. The PCRampli®ed c-myc AS cDNA was detectable only in the ponasterone-treated pINDc-myc AS cells at cycle 33; whereas, the PCR-ampli®ed c-myc cDNA in this clone was barely detectable even increasing the number of PCR cycles, up to 35 cycles. The pINDc-myc AS cells not exposed to ponasterone and the hormone treated control cells showed comparable levels of the PCRampli®ed c-myc cDNA at 35 cycles and no detectable amounts of PCR-ampli®ed c-myc AS cDNA at 33 cycles. b-actin was used as an internal control for the amount of RNA used in all RT ± PCR reactions.
The levels of Myc protein in pINDc-myc AS cells were measured by Western blot analysis. The results in Figure 3c indicated that the treatment with ponasterone resulted in an evident Myc downregulation (threefold) after 24 h, similar to what was observed with the previous single-dose hormone regimen and consistent with RT ± PCR data. A further decrease (sixfold) of Myc levels in the c-myc AS clone was observed after 48 h of ponasterone exposure (two doses of the hormone). HSP72/73 detection was done as control for the amount of total protein used ( Figure 3c ). The low proliferation rate of M14 pINDc-myc AS cells is due to the prevention of G1?S transition
In order to determine which phase of the cell cycle was aected by the decreased Myc protein expression we have analysed the cell cycle distributions in pINDc-myc AS cells, exposed to repeated doses of ponasterone A, by BrdUrd incorporation and¯ow cytometry. This analysis, performed at dierent times after c-myc AS induction, revealed, as expected, an increasing accumulation of the hormone-treated pINDc-myc AS cells in the G 1 cell cycle phase as the time proceeded ( Figure  4a ), pINDc-myc AS cells accumulated in the G 1 phase of the cell cycle (52% compared to 29% of control cells) as early as 24 h from hormone exposure; after 72 h of hormone treatment more than 80% of the cells were blocked in G 1 , as compared to the 43% of control cells. The arrest in the G 1 phase was associated to a concomitant depletion of cells from both the S and G 2 / M cell cycle compartments. The block in the G 1 phase was also con®rmed in cells continuously exposed to BrdUrd for 24 h, in order to label the entire cycling cell population. As shown in Figure 4b The prevention of G1?S transition, following inhibition of c-myc expression, correlates with an increase of p27 kip1 level, a decrease of cdk2 kinase activity and a decrease of pRb phosphorylation
Since Myc is known to act as an upstream regulator of cdks activity, we investigated whether down-regulation of Myc protein levels could aect the expression of the main molecules that control cell cycle entry and progression. The expression levels of cyclin E, cyclin A, p27 kip1 , p21 cip1 and cdk2 as well as of the cdc25A phosphatase were determined in pINDc-myc AS and (Figure 5a ). The Western blot analysis, performed after 48 h from hormone exposure, revealed a decrease of both cyclin E (1.5-fold) and cyclin A (threefold) expression, consistent with the accumulation of cells in the G 1 phase. The cdk2 content was also decreased by about threefold in M14 pINDc-myc AS cells exposed to the hormone. In addition, a more than 10-fold reduction was observed in p21 cip1 protein levels. Cdc25A levels were slightly decreased after c-myc AS induction (1.1-fold). By contrast, an increase in the levels of p27 kip1 of more than threefold was detected. The expression levels of cyclin E, cyclin A, cdk2, p21 cip1 , p27 kip1 and cdc25A in empty vector-transfected cells appeared quite similar to those of the non transfected parental cells. Consistent with the Western blot data cdk2-associated kinase activity, evaluated in pINDc-myc AS cells after 48 h from hormone exposure, was found decreased by about 70%, as compared to those of control cells (Figure 5b ).
In addition, since one of the major target of cdk2 kinase activity is pRb, we have also analysed the status of pRb in pINDc-myc AS cells induced with the hormone. Western blot analysis of pRb demonstrates that Myc down-regulation led to an increased amount of hypophosphorylated pRb (Figure 5c , top).
It is known that the degradation of p27 kip1 is dependent on the phosphorylation at the threonine 187, then we decided to test whether the accumulation of p27 kip1 protein could be due to a decrease of its degradation analysing the phosphorylation status of p27 kip1 . p27 kip1 was immunoprecipitated and then analysed by Western blot using an antibody recognizing the phosphothreonine at position 187. Figure 5c , bottom, shows more than threefold decrease in the amount of phospho-p27 kip1 in pINDc-myc AS cells treated with the hormone, suggesting that Myc protein regulates the pathway of phosphorylation of p27 kip1 .
To investigate whether the overexpression of p27 kip1 in the M14 pINDc-myc AS cells treated with the hormone could also be ascribed to an accumulation of p27 kip1 mRNA, Northern blot analysis of total RNA was performed. The analysis showed that the level of p27 kip1 mRNA did not signi®cantly change following c-myc AS induction (Figure 5d ).
The increased levels of p27 kip1 expression correlate with activation of programmed cell death
In order to determine the contribution of apoptosis to the decrease of cell number observed in pINDc-myc AS cells after down-regulation of Myc protein expression, DNA fragmentation analysis was performed on the same samples previously examined for cell proliferation. Two dierent methods of analysis by¯ow cytometry (Propidium Iodide-staining of the DNA and TUNEL assay) were used on each sample. TUNEL assay was used to exclude necrosis that could not be accurately discriminated using PI-staining. Figure 6a shows the percentages of apoptotic cells in pINDc-myc AS and control cultures exposed to the hormone, as determined by¯ow cytometry, either in the sub-G 1 region of the¯ow cytometric DNA content distributions or as FITC-dUTP associated positivity. The results obtained with the two methods of analysis were superimposable, indicating that no necrosis had occurred after treatment of the cells with the hormone. The hormone-induced down-regulation of Myc protein activates apoptotic cell death only in the pINDc-myc AS clone as compared to the vector transfected cells. Apoptosis was already evident after 48 h of hormone exposure, the apoptotic cell percentages being 20 and 17% as calculated by PI-staining and TUNEL assay, respectively. The inhibition of cell proliferation obtained at 72 h of hormone exposure resulted in a marked increase of programmed cell death, with apoptotic cell percentages of 41 and 48% calculated with the two methods of analysis, respectively. Only 2 ± 3% of the control cell population showed evidence of apoptotic cell death. Morphological analysis of the cell cytospins further con®rmed the presence of apoptosis in the pINDc-myc AS clone (data not shown). Since p27 kip1 overexpression has been demonstrated to activate apoptosis in dierent tumor types, we sought to determine the eect of an ectopic p27 kip1 expression in M14 melanoma cells. To better evidence the role of p27 kip1 in the activation of apoptotic program in M14 melanoma cells we also transfected the pINDc-myc AS clone with two dierent p27 kip1 mutants that have been demonstrated to fail in blocking the cells in G 1 phase (Vlach et al., 1997) . The p27 wt , p27 ck7 and p27 k7 expression vectors were transiently co-transfected with the GFP-spectrin expression plasmid in pINDc-myc AS cells and the DNA content pro®le of transfected cells was analysed by means of two-color¯ow cytometry (Figure 6b ). In fact, gating out GFP-positive cells and analysing the cell cycle distribution of this population 48 h after transfection, we evidenced 40% of apoptosis in the pINDc-myc AS cells overexpressing p27 wt (panels c and c'). By contrast, apoptosis was undetectable in GFPpositive cells transfected with the p27 ck7 mutant (panels d and d') and with the p27 k7 mutant (panels e and e') as well as with the empty vector (panels b and b'). The In addition, to exclude the possibility that the apoptotic program could be activated by the G 1 block produced by p27 kip1 , we have studied the eect of an ectopic expression of a dominant negative cdk2 mutant (CDK2 DN) in pINDc-myc AS M14 cell clone. Cells were co-transfected with GFP-spectrin expression plasmid and pCMV/CDK2 DN or pCMV empty vector and the DNA content pro®le of transfected cells was analysed as described above. Indeed, the inactivation of the cdk2 kinase was not able to induce apoptosis even though about 70% of the cells were accumulated in the G 1 phase (Figure 6c ). The fraction of the cells in the sub-G 1 region was less than 10%. In addition, the analysis of the expression of the p27 kip1 protein following inactivation of the cdk2 kinase demonstrated that no increase in p27 kip1 level occurred (Figure 6d) , strongly supporting the hypothesis that p27 kip1 per se could promote apoptosis.
Discussion
The c-myc proto-oncogene has been shown to play a role in melanoma cell proliferation. In fact, in previous reports we have shown that inhibition of Myc protein expression leads to apoptosis in several melanoma cell lines (Leonetti et al., 1996) . However, the Myc- controlled pathways involved in the observed apoptosis are still obscure. In the present study we developed a melanoma model in which reduction of endogenous c-myc expression can be ectopically driven in a hormone-inducible way, providing a useful tool to study the molecular events controlled by c-myc which could be responsible for the activation of programmed cell death. Data herein reported provide, for the ®rst time in melanoma cells, experimental evidence that switching o' the synthesis of Myc protein, the levels of the kinase cyclin-dependent inhibitor p27 kip1 increase, preventing G 1 ?S transition and promoting apoptosis.
The 20 mM dose of the hormone/ponasterone given every 24 h induces the transcription of antisense c-myc RNA and is needed to reduce Myc expression at a level that is critical for cell proliferation. Other authors have shown that cell proliferation was inhibited by inducing the expression of c-myc antisense mRNA in a Small Cell Lung Carcinoma cell line, even though no Myc down-regulation and cell cycle perturbations were detected (van Waardenburg et al., 1997) . Conversely, our data demonstrate that the induction of c-myc AS transcripts in M14 cells causes a reduction of Myc levels and an inhibition of proliferation of exponentially growing cells. This strongly favors the hypothesis that the observed inhibition of cell proliferation is really to be ascribed to the down-regulation of Myc protein. We have previously demonstrated that antisense phosphorothioate oligodeoxynucleotides (ODNs) targeted to the c-myc mRNA can inhibit cell proliferation in melanoma cells both in vitro and in vivo (Leonetti et al., 1996) and that Myc protein reduction also makes the melanoma cells more sensitive to cis-platin treatment (Citro et al., 1998) . In these studies it has been reported that the decreased level of Myc protein obtained by ODNs treatment accumulated the cells in the S phase of the cell cycle. Data herein reported demonstrate that the inhibition of cell proliferation, following Myc protein down-regulation, is due to an arrest of the cells in the G 1 phase. These apparently contrasting results could be explained considering that: (1) To avoid enzymatic degradation ODNs must be modi®ed in their chemical composition and this could aect the ODNs binding anity to the target mRNA (Lesnikowski et al., 1990) . (2) Modi®ed ODNs can also react with other cellular targets (such as enzymes or cellular structural proteins (Burgess et al., 1995; Stein, 1998; Krieg and Stein, 1995) . (3) To be eective against melanoma cells modi®ed ODNs must be administered at high doses. Thus, the use of modi®ed ODNs, employed at high doses, can render signi®cant' the non-sequence speci®c interactions of ODNs, partially masking the sequence speci®c eects of the antisense ODNs and interfering in the evaluation of the molecular mechanisms studied. An experimental model based on the inhibition of gene function induced directly inside the cells appears to be more appropriate to investigate the role of the cell cycle-related Myc protein in the induced-apoptosis. Our model allowed us to directly link the down-regulation of Myc protein with the observed eects on proliferation, thus avoiding interference possibly caused by non-antisense mechanism.
The Myc down-regulation-mediated G 1 block is also strongly supported by the decreased expression of cyclins E and A, which are cell cycle regulators at the G 1 ?S transition and at the S-progression/S?G 2 transition, respectively. These observations are in agreement with results from other authors, who demonstrated that a deregulation of c-myc is associated to an increase of cyclin E expression (Jansen-Durr et al., 1993; Daksis et al., 1994; Hanson et al., 1994; Hoang et al., 1994) . However, even though evidences have been provided that c-myc is able to directly transactivate the expression of cyclin E, the mechanism involved remains unclear (Leone et al., 1997; PerezRoger et al., 1997) . In addition, the observed decrease in cyclin A levels could be ascribed to a reduced activation of the cyclin A promoter by the cyclin E/ cdk2 kinase. The cyclin E-cdk2 complex activity is neutralized by p27 kip1 that increased its levels by threefold following Myc down-regulation. In fact, a signi®cant reduction of cdk2 kinase activity was also found. These data are consistent with those from others who demonstrated that an increase of the Myc levels is related to the increase of cdk2-associated kinase activity (Vlach et al., 1996) or that in c-myc-null cells the activities of all cyclin-cdk complexes are reduced .
The increased level of p27 kip1 observed in our model is not regulated by a transcriptional mechanism since the amount of p27 kip1 RNA did not change in cells with inhibited Myc expression. We hypothesize a regulation of this CKI due to reduced p27 kip1 degradation. It has been recently proposed that c-myc drives the synthesis of a putative p27 kip1 -sequestering protein, which renders the hyperphosphorylated p27 kip1 available for ubiquitination . Accordingly, it is likely that the down-regulation of Myc protein could prevent the synthesis of this putative protein making p27 complex and the regulation of p27 kip1 polyubiquitination by this complex is dependent on the prior phosphorylation of p27 kip1 on threonine 187. It is likely that in the Myc down-regulated cells, both the inhibition of p27 phosphorylation and the downregulation of Cul1, contribute to the increase of p27 stabilization.
In addition, since p27 kip1 is a substrate of the cyclin E/cdk2 phosphorylating activity (Shea et al., 1997) , it is also possible that the reduction of cyclin E levels decreases p27 kip1 phosphorylation, thus contributing to render the CKI not available for proteasome degradation. Indeed, we found that the amount of phosphorylated p27 kip1 decreases of about threefold following Myc down-regulation, strongly supporting the hypothesis that the accumulation of p27 kip1 is to be ascribed to a reduced degradation of the protein. On the other hand, Oncogene p27 kip1 -mediated apoptosis in melanoma cells I D'Agnano et al the decrease of the activity of cyclin E/cdk2 complex is also demonstrated by the increase of the amount of hypophosphorylated fraction of pRb.
The increase of p27 kip1 was found to be associated to a very strong decrease (10-fold) of the other CKI p21 cip1
. Similar results were reported by Mateyak et al. (1999) , who demonstrated that in c-myc null cells overexpression of p27 kip1 was accompanied by a quite complete disappearance of p21 cip1 . Our results also show that down-regulating Myc protein, melanoma cells underwent apoptotic cell death. The role of c-myc in the apoptotic processes was de®nitively established in the early 1990s by Cleveland, Evan and their colleagues, who have extensively demonstrated that c-myc is able to activate apoptosis (Evan et al., 1992) . Indeed, cells where c-myc is enforced undergo apoptosis following growth factor withdrawal. More recently Evan himself and Littlewood have proposed the appealing idea that c-myc does not act as a death eector per se but instead sensitizes the cells to a variety of apoptotic triggers, thus supporting the hypothesis that c-myc has intrinsic functions related to cell death (Evan and Littlewood, 1998) .
In this study we clearly demonstrate that one stimulus which could activate apoptosis in melanoma cells is the down-regulation of Myc protein. It is likely that the down-regulation of Myc protein by itself could mimic the growth factor withdrawal in a cell type in which the proliferative stimulus is assured by the inactivation of the p16-cyclinD/cdk4-pRb pathway (Bartkova et al., 1996; Maelandsmo et al., 1996) . Therefore, the cells committed to proliferate are poised in unfavorable conditions by diminishing Myc levels and therefore undergo apoptosis. We hypothesize that this apoptosis is mediated by the increase of p27 kip1 . To support this hypothesis we have investigated the eects of an ectopic overexpression of p27 wt and two p27 mutants (ck 7 and k
7
) that fail to block the cells in the G 1 phase (Vlach et al., 1997) . The results herein reported show that the p27 wt activates the apoptotic program, while the two mutants do not. In addition, we have also investigated whether the block in the G 1 cell cycle phase caused by p27 wt could act per se as death eector. We show that an ectopic expression of a CDK2 DN (Van den Heuvel and Harlow, 1993) was able to arrest in G 1 phase about 70% of the cell population but no signi®cant apoptosis was evidenced and did not increase the p27 kip1 levels. This strongly supports the idea that p27 kip1 is directly responsible for the promotion of apoptosis in the melanoma cell type, in accordance with data reported in the literature (Katayose et al., 1997; Wang et al., 1997) .
In conclusion, data herein reported evidenced, in the melanoma tumor type in which the p16-cyclinD/cdk4-pRb G 1 checkpoint is defective, an alternative pathway of growth-and death-regulation mediated by the increase of p27 kip1 levels. This is particularly relevant in view of the identi®cation of new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells, thus providing important information for improving melanoma patients management.
Materials and methods

Plasmid preparation
pINDc-myc AS was generated by subcloning from pBJ3O-Myc MER (kind gift from Bruno Amati, DNAx Institute, San Francisco, USA) the complete c-myc cDNA fragment into BamHI site of pIND downstream of the ecdysone response element (Invitrogen, San Diego, CA, USA) which contains the neomycin (G418) resistance gene. pVgRXR, which encodes for a heterodimer of the ecdysone receptor, was purchased by Invitrogen and contains the Sh ble gene that permits stable selection in mammalian cells in the presence of zeocyn. Bruno Amati (Vlach et al., 1996) ) and the pCMV/CDK2 DN (Van den Heuvel and Harlow, 1993) . The pCMVEGFP-spectrin expression vector was a kind gift from Andrew J Beavis (Kalejta et al., 1997) .
Cell culture and DNA transfections M14 human melanoma cell line was cultured in RPMI-1640 medium supplemented with fetal calf serum (10%), gentamycin (0,1%) and L-glutamine (1%) at 378C in a 5% CO 2 /95% air atmosphere in a humidi®ed incubator. Generation of stable c-myc AS inducible expression cell clones was achieved employing the Ecdysone-Inducible Expression System (Invitrogen, San Diego, CA, USA). Brie¯y, this system is based on the molting induction system found in Drosophila and modi®ed for inducible expression in mammalian cells. The system uses the steroid hormone ecdysone analog, Ponasterone A, to activate the expression of the gene of interest via a heterodimeric nuclear receptor. Two mg of double-stranded DNA of both pINDc-myc AS and pVgRXR plasmids were mixed in Optimem (GIBCO, BRL) with 10 ml of lipofectamine reagent (GIBCO, BRL) and incubated, for 5 h, with 1610 5 M14 cells the day after seeding, according to the manufacturer's instructions. RPMI fresh medium supplemented with 10% FCS was added and after 48 h culturing, the transfected cells were maintained for 3 weeks in the presence of both G418 (GIBCO, BRL) and zeocyn (Invitrogen, San Diego, CA, USA). G418/Zeocyn resistant clones were isolated and selected from pINDc-myc AS as well as from the empty vector (pINDneo) ) and 2 mg of pCMVEGFPspectrin plasmids, mixed in Optimem containing 25 ml lipofectamine reagent and incubated, for 5 h, with 3610 5 cells (100 mm dishes) the day after seeding, according to the manufacturer's instructions. Afterwards, the transfected cells were maintained in fresh growing medium for an additional time of 48 h and then were trypsinized for¯ow cytometric apoptosis detection.
RNA extraction, Northern blot and semi-quantitative RT ± PCR
Total RNA was prepared by guanidium thiocyanate method of extraction. Northern blots were made using standard For semi-quantitative RT ± PCR, 1 mg of total RNA from each sample were reverse-transcribed in a 20 ml volume reaction using 50 pmoles of random examers with 200 units M-MLV reverse transcriptase (GIBCO, BRL), according to the manufacturer's instructions. PCR was carried out in 100 ml volume containing 0.25 mM of each dNTP, 20 pmoles/ml of each oligonucleotide primer, 2 mM MgCl 2 , 200 mM (NH 4 )2SO 4 , 750 mM tris-HCl pH 9.0, 0.1% Tween 20, using 1 ± 2 ml of RT reaction mixture and 2.5 units of Thermoprime Plus DNA polymerase (Advanced Biotechnologies LTD). The mixtures were subjected to dierent PCR cycles, as indicated, including the ®rst denaturation cycle at 948C for 4 min; denaturation at 948C for 30 s; annealing for 30 s and extension at 728C for 1 min. Ampli®cation products (20 ml) were analysed by electrophoresis on a 1.5% Agarose gel stained with ethidium bromide. Primers and annealing temperatures used were as follows: c-myc (Hmyc01 ATTCTCTGCTCTCCTCGA; Hmyc02 TCTTGGCAGCAGGATAGT, T A =578C); c-myc AS (Hmyc03 CTCCTCGTCGCAGTAGAA; BGHrev TA-GAAGGCACAGTCGAGG, T A =578C); b-actin (sense GCGCGGCGTAGCCCCCGTCAG; antisense CGCGGC-AGGAAGCCAGGCCCC, T A =578C).
Apoptosis detection
Apoptosis was analysed in pINDc-myc AS and control stable clones by¯ow cytometry using both Propidium Iodide (PI)-staining and TUNEL assay. Cells induced with ponasterone A were harvested, washed once in PBS and either stained with PI (50 mg/ml, Sigma Chemical Co.) in PBS containing RNase A (75 Ku/ml, Sigma Chemical, Co.) or processed for TUNEL assay as previously described . The analysis of apoptosis in pINDc-myc AS cells transiently transfected with expression vectors containing p27 wt , p27 ck7 , p27 k7 was performed bȳ ow cytometry after PI-staining. Cells transfected as described above were trypsinized after 48 h culturing in fresh medium and either analysed for DNA content or sorted for Western blot analysis. For DNA content analysis the transfected cells were ®xed in 80% ethanol and stained with PI (50 mg/ml, Sigma Chemical Co.) in PBS containing RNase A (75 KU/ml, Sigma Chemical, Co.). Two-color¯ow cytometry was performed, simultaneously measuring GFPspectrin (green channel) and PI (red channel)¯uorescence, using a FACScan¯ow cytometer (Becton Dickinson, Sunnyvale, CA, USA). The gates to analyse DNA content distribution of both GFP-spectrin/pBP/p27 wt , p27 ck7 , p27 k7 and pCMV/CDK2 DN transfected cells were established by measuring background levels of empty vectors transfected cell¯uorescence. For Western blot analysis, transfected cells were sorted on the basis of the GFP-spectrin positivity, using an EPICS 541¯ow cytometer (Coulter Electronics Inc), and then analysed for Western blot as described successively.
Cell cycle analysis
Cell cycle analysis of pINDc-myc AS and control stable clones was performed after bromodeoxyuridine (BrdUrd, Sigma, St. Louis, USA) incorporation. Both BrdUrd pulselabeling and continuous-labeling experiments were carried out. Pulse-labeling experiments were performed at 24, 48 and 72 h from hormone induction, by adding 10 mM BrdUrd to the medium during the last 30 min before analysis. For BrdUrd continuous-labeling experiments the stable cell clones were continuously exposed for 24 h to 10 mM BrdUrd at 48 h of hormone induction. At the indicated times the cells were harvested, washed once in PBS, ®xed in 70% ethanol and stored at 48C until analysis. Then cell suspensions were rinsed with cold PBS and incubated with 4 N HCl for 20 min at room temperature to partially denature DNA. Cells were washed twice with borax-borate buer (pH=9.1) to neutralize the acid pH and once with PBS. The samples were incubated with mouse monoclonal antibody antibromodeoxyuridine (Boehringer Mannheim, Monza, Italy) diluted 1 : 50 in complete medium containing 0.5% Tween-20 (Calbiochem, San Diego, CA, USA) at 48C for 1 h. After washing twice in PBS, cells were exposed to FITCConjugated F(ab') rabbit anti-mouse (Dako, SA, Glostrup, Denmark) at dilution 1 : 20 in PBS at 48C for 1 h. Finally, the cells were washed twice with PBS, stained with a solution containing 50 mg/ml PI and 75 KU/ml RNase in PBS for 30 min at room temperature. The samples that had not been incubated with monoclonal antibody anti-bromodeoxyuridine were used as negative controls. Twenty thousand events/ sample were acquired using a FACScan cyto¯uorimeter (Becton Dickinson, Sunnyvale, CA, USA). The analysis was performed using a CellQuest software package (Becton Dickinson).
Western blot analysis
Lymphocytes and M14 cells were solubilized in lysis buer (0.01 M Tris-HCl [pH 7.5], 0.144 M NaCl, 0.5% Nonidet P-40, 0.5% sodium dodecyl sulfate [SDS], 0.1% aprotinin, 10 mg/ml leupeptin, and 2 mM phenylmethylsulfonyl¯uoride) and treated by 10 s of sonication. The protein content in the dierent samples was quanti®ed using the BCA protein assay (Pierce Chemical Co., Rockford, IL, USA). Thirty-microgram aliquots of protein were subjected to 10% SDSpolyacrylamide gel electrophoresis. The resolved proteins were blotted to a nitrocellulose membrane by semidry electric transfer, and the membranes were blocked in TBS buer (20 mM tris Base, 137 mM sodium chloride, 1 M hydrochloric acid, pH 7.6) containing 0.2% blotting grade blocker non fat milk (Biorad, Hercules, CA, USA) for 1 h. Blots were then incubated with the primary antibodies: anti-human cyclin D1 (clone HD11, Calbiochem, Cambridge, UK), anti-human cdk4 (clone H-22, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-human p16 (clone N-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) MoAbs.
Cells (1610 6 In vitro kinase assay Cells were lysed by addition of ice-cold lysis buer (50 mM HEPES, 250 mM NaCl, 0.1% Tween-20, 1 mM EDTA, 2.5 mM EGTA, 10% Glycerolo, 10 mM b-glycerol-phosphato, 1 mM DTT) containing 1 mM phenylmethylsulfonyl uoride, 10 mg/ml pepstatin, 25 mg/ml leupeptin, 25 mg/ml aprotinin, 50 mM sodium¯uoride, 1 mM sodium orthovanadate. The lysates were sonicated, centrifuged at 13 000 r.p.m. for 30 min at 48C and total proteins were quanti®ed using the BCA protein assay (Pierce Chemical Co.). Cyclin A and cdk-2 immunoprecipitations were performed using 200 mg of proteins from cell lysate. Anti-human cdk2 (Ab-1 Calbiochem) and cyclin A (clone, BF683, Calbiochem, Cambridge, UK) Mabs were used. The immunocomplexes were bound to protein A-agarose, centrifuged and then washed four times with lysis buer and twice with kinase buer preparative (50 mM HEPES, 1 mM DTT). Fifty ml kinase buer (50 mM HEPES, 10 mM MgCl 2 , 1 mM DTT, 2.5 mM EGTA, 10 mM b-glycerol-phosphato, 0.1 mM sodium orthovanadate, 1 mM sodium¯uoride) was added together with 2 mg histone H1 and 50 mM ATP, 10 mCi [g-32 P]ATP to the cyclin A-or cdk2-immunocomplexes, and the reaction was incubated at 308C for 30 min. The reaction was stopped by the addition of 25 ml 46 Laemmli sample buer and boiling for 5 min. The reaction products were analysed on a 10% acrylamide gel, stained with Coomassie blue (to control for the same amounts of histone H1 protein added), dried and exposed to Kodak X-AR ®lm.
Immunoprecipitation
Protein extraction was done as described above and 1 mM okadaic acid was added at the lysis buer. Immunoprecipitation was performed using an anti-human p27 kip1 (Upstate Biotechnology, Lake Placid, NY, USA) and the immunocomplexes were bound to protein A-agarose, centrifuged and then washed four times with lysis buer. The reaction products were analysed on a 12% acrylamide gel, the resolved proteins were blotted to a nitrocellulose membrane by semidry electric transfer, and the membranes were processed as described above using a rabbit anti-phosphop27 kip1 antibody (Zymed Laboratories, San Francisco, CA, USA).
